Mirna Profiling for the Early Detection and Clinical Monitoring of Diabetic Kidney Disease

DiStefano, Johanna K.

doi:10.2217/bmm-2016-0301

Cited by 3 publications

(1 citation statement)

References 29 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNA are small (20–25 nucleotides) non-coding RNA particles that modify the expression of target genes via promotion or inhibition of degradation of respective mRNAs based on their complementarity. Given their crucial impact on gene expression, they are now considered as new disease biomarkers and potential therapeutic targets or even therapeutic agents, and these new perspectives also apply to CKD and DKD [ 44 , 45 , 46 ]. For example, some miRNAs may interact with sirtuins, affect autophagy and apoptosis and directly influence the fate of the kidney cells and endothelial and vascular smooth muscle cells [ 47 ].…”

Section: Sglt2i As Antioxidative and Anti-inflammatory Agents In Dkd And Other Models Of Kidney Injurymentioning

confidence: 99%

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

Winiarska

Knysak

Nabrdalik

et al. 2021

IJMS

View full text Add to dashboard Cite

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney disease (DKD) remains one of the leading long-term complications of T2D. Several lines of evidence indicate that glucose-lowering agents prevent the onset and progression of DKD in its early stages but are of limited efficacy in later stages of DKD. However, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor (GLP-1R) antagonists were shown to exert nephroprotective effects in patients with established DKD, i.e., those who had a reduced glomerular filtration rate. These effects cannot be solely attributed to the improved metabolic control of diabetes. In our review, we attempted to discuss the interactions of both groups of agents with inflammation and oxidative stress—the key pathways contributing to organ damage in the course of diabetes. SGLT2i and GLP-1R antagonists attenuate inflammation and oxidative stress in experimental in vitro and in vivo models of DKD in several ways. In addition, we have described experiments showing the same protective mechanisms as found in DKD in non-diabetic kidney injury models as well as in some tissues and organs other than the kidney. The interaction between both drug groups, inflammation and oxidative stress appears to have a universal mechanism of organ protection in diabetes and other diseases.

show abstract

Section: Sglt2i As Antioxidative and Anti-inflammatory Agents In Dkd And Other Models Of Kidney Injurymentioning

confidence: 99%

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

Winiarska

Knysak

Nabrdalik

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

Extranodal lymphoma: pathogenesis, diagnosis and treatment

Yang,

Xun,

et al. 2023

Mol Biomed

View full text Add to dashboard Cite

Approximately 30% of lymphomas occur outside the lymph nodes, spleen, or bone marrow, and the incidence of extranodal lymphoma has been rising in the past decade. While traditional chemotherapy and radiation therapy can improve survival outcomes for certain patients, the prognosis for extranodal lymphoma patients remains unsatisfactory. Extranodal lymphomas in different anatomical sites often have distinct cellular origins, pathogenic mechanisms, and clinical manifestations, significantly influencing their diagnosis and treatment. Therefore, it is necessary to provide a comprehensive summary of the pathogenesis, diagnosis, and treatment progress of extranodal lymphoma overall and specifically for different anatomical sites. This review summarizes the current progress in the common key signaling pathways in the development of extranodal lymphomas and intervention therapy. Furthermore, it provides insights into the pathogenesis, diagnosis, and treatment strategies of common extranodal lymphomas, including gastric mucosa-associated lymphoid tissue (MALT) lymphoma, mycosis fungoides (MF), natural killer/T-cell lymphoma (nasal type, NKTCL-NT), and primary central nervous system lymphoma (PCNSL). Additionally, as PCNSL is one of the extranodal lymphomas with the worst prognosis, this review specifically summarizes prognostic indicators and discusses the challenges and opportunities related to its clinical applications. The aim of this review is to assist clinical physicians and researchers in understanding the current status of extranodal lymphomas, enabling them to make informed clinical decisions that contribute to improving patient prognosis.

show abstract

Biomarkers in Medicine : Foreword

Tarring

2017

Biomark. Med.

View full text Add to dashboard Cite

Mirna Profiling for the Early Detection and Clinical Monitoring of Diabetic Kidney Disease

Cited by 3 publications

References 29 publications

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

Extranodal lymphoma: pathogenesis, diagnosis and treatment

Biomarkers in Medicine : Foreword

Contact Info

Product

Resources

About